DUBLIN--(
BUSINESS WIRE
)--The
"State of the Biopharmaceutical Industry 2024 Edition"
report has been added to
ResearchAndMarkets.com's
offering.
While the fight against COVID-19 is not in the distant past, it has been already overshadowed by a range of macroeconomic and geopolitical factors. At the same time, ongoing drug pricing and reimbursement constraints, regulatory pressures, and biotech funding instability will continue to test pharmaceutical industry in the coming years.
The State of the Biopharmaceutical Industry 2024 report examines the business environment and trends that are going to shape the biopharmaceutical industry in 2024. The report highlights the most impactful emerging technologies, industry trends, regulatory trends, and microeconomic factors that are going to impact and dominate the industry throughout 2024.
Post-COVID-19 recovery is met by a range of macroeconomic and geopolitical challenges.
Genomics, IO drug development, personalized/precision medicine and CGTs will dominate as the most impactful trends in the biopharmaceutical industry in 2024.
Among the most impactful trends, cell and gene therapies will be the key focus in 2024.
Geopolitical conflicts, inflation, and drug pricing pressures will be the top hindrances for pharmaceutical sector growth.
Vertical integration, patent expiry of biologics, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry.
Big data and AI will continue to dominate as transformational forces in the healthcare sector in 2024.
Across pharma value chain components, drug development and end users experience are lagging behind with innovation adoption.
The biopharmaceutical industry is more optimistic about industry growth in the next 12 months as compared to 2023, but level of optimism is still below 2022 levels.
A total of 44% of survey respondents expressed an optimistic or very optimistic sentiment on the biotech funding recovery in 2024.
Oncology, CNS, and infectious diseases will be the dominant areas for clinical trials initiated in 2023.
Oncology remains the single largest therapy area going into 2024, but metabolic disorders display the highest growth.
The IRA is believed to open the door to government price negotiation across all pharmaceuticals.
Key Highlights
There is hope for more stability in 2024, but the road is still rocky.
CGT is the trend that will continue to have the greatest impact on the pharmaceutical industry in 2024.
Inflation, geopolitical conflicts, and drug pricing and reimbursement-related concerns will be the leading impediment to industry growth.
Vertical integration, patent expiry of biologics, and ESG factors will have the most positive impacts on industry.
AI is set to bring disruptive change in pharmaceutical industry
Optimism about the pharmaceutical sector's growth prospects recovered from the lows seen in 2023.
Report Scope
Benchmark the impact of major themes on the biopharmaceutical industry in 2024, including: emerging technologies, regulatory trends, macroeconomic trends, industry trends.
Identify themes that will have the greatest positive or negative impact in 2024.
Capture opinions on these themes from industry respondents.
Predict the industry's growth prospects in 2024.
Key Topics Covered:
Executive Summary
Study Design
Emerging Industry Trends
Emerging Regulatory and Macroeconomic Trends
Emerging Technologies
Industry's Growth Prospects
Watch Outs
Summary of Key Findings
A selection of companies mentioned in this report includes
AbbVie
Absci
Actinium Pharmaceutical
Adaptimmune
Aetna
Altaris Capital Partners
Alvotech
Amgen
Aqemia
Astellas Pharma
AstraZeneca
Bayer
BenevolentAI
Berkshire Sterile Manufacturing (BSM)
Biocon Biologics
Biogen
BioNTech
Biosynth
Bio-Thera Solutions
Boehringer Ingelheim
BridgeBio Pharma
Bristol Myers Squibb
Catalent
Celares Gmbh
Celltrion
Cigna's
CVS Health
Day One Biopharmaceutical
Dr Reddy's lab
Eli Lilly
Exelead
Express Scripts
Exscientia
Ferring Pharma
Formycon
Fresenius Kabi
Fuji Pharma
Genmab
Geron Corp
IASO Bio
ImmunityBio
Incyte
Insilico
Insud Pharma
Johnson & Johnson
Junshi Bio
Juventas
Karuna Therapeutics
Lonza
mAbxience
Madrigal Pharmaceuticals Inc
Merck & Co
Metrics Contract Services
Mochida Pharmaceutical
Moderna
Mylan
Novartis
Novo Nordisk
Optum
Amedisys
Pear Therapeutics
Pfizer
Regeneron
Roche
Samsung Bioepis
Sandoz
Sanofi
Seres Therapeutics
Sharp Services Inc
STgen Bio
Strides Pharma Science
Synaffix
Syndax Pharmaceutical
Teladoc Health
TheraPlatform
Tricida
UnitedHealth
Veranova
Verona Pharma Plc
Viatris
Zhaoke Ophthalmology
For more information about this report visit
https://www.researchandmarkets.com/r/kj2v51
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.